ReviewPaediatric drugs2015
Management of retinoblastoma in children: current status.
Review in Paediatric drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 37 citations in OpenAlex.
- Article
- Liver metastasis of retinoblastoma.Ecancermedicalscience · 2025Article
- Risk of secondary tumours in patients with non-metastatic and metastatic human retinoblastoma.Eye (London, England) · 2023Article
- SCARA5 suppresses the proliferation and migration, and promotes the apoptosis of human retinoblastoma cells by inhibiting the PI3K/AKT pathway.Molecular medicine reports · 2021Article
- Effect ofInternational journal of ophthalmology · 2021Article
- Paediatric Formulation: Design and Development.International journal of molecular sciences · 2020Article
- Preimplantation genetic diagnosis for retinoblastoma survivors: a cost-effectiveness study.Reproductive biomedicine & society online · 2020Article
- Tridimensional Retinoblastoma Cultures as Vitreous Seeds Models for Live-Cell Imaging of Chemotherapy Penetration.International journal of molecular sciences · 2019Article
- Effect of dexmedetomidine anesthesia on respiratory function in pediatric patients undergoing retinoblastoma resection.Oncology letters · 2019Article
- Intra-arterial chemotherapy for unilateral advanced intraocular retinoblastoma: Results and short-term complications.Medicine · 2018Observational
- The technique of superselective ophthalmic artery chemotherapy for retinoblastoma: The Garrahan Hospital experience.Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences · 2018Article
- Recent advancements in the management of retinoblastoma and uveal melanoma.F1000Research · 2018Review
- Risk of metastasis and orbital recurrence in advanced retinoblastoma eyes treated with systemic chemoreduction versus primary enucleation.Pediatric blood & cancer · 2017Article
- Incidence Patterns and Trends of non-Central Nervous System Solid Tumours in Children and Adolescents. A Collaborative Study of the Spanish Population Based Cancer Registries.Journal of Cancer · 2016Article
- Article
- Ophthalmic artery chemosurgery for eyes with advanced retinoblastoma.Ophthalmic geneticsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, there have been dramatic changes in the management of intraocular retinoblastoma. Intraocular retinoblastoma is a highly curable malignancy and current treatments are aimed to preserve vision while reducing the late effects such as treatment-induced secondary malignancies. The advent of intra-arterial chemotherapy changed the treatment paradigm from systemic treatment with chemotherapy to local treatment, and new questions emerged. While intra-arterial chemotherapy achieved encouraging results, only experience from major referral centers is reported, so its indications, advantages and risks are still to be elucidated. Many factors should be considered when choosing the appropriate conservative therapy. When the disease has extended outside the eye, the chances of cure are significantly lower and treatment should be tailored by the presence of pathology risk factors such as invasion of the choroid, the optic nerve, and the sclera. Adjuvant therapy is decided upon this information. Children with overt extraocular disease are treated with higher dose neoadjuvant therapy followed by delayed enucleation and adjuvant therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.